Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS

Abstract

XP13512 1,200 mg, taken once daily, significantly improved restless legs syndrome (RLS) symptoms compared with placebo and was generally well tolerated in adults with moderate to severe primary RLS.